Literature DB >> 6123257

Absorption, enterohepatic circulation, and excretion of 5-aminosalicylic acid in rats.

A Shafii, J R Chowdhury, K M Das.   

Abstract

After oral administration of sulfasalazine, the majority of the administered dose reaches the colon, where it is split into 5-aminosalicylic acid (5-ASA) and sulfapyridine. 5-ASA is believed to be the effective component in the treatment of inflammatory bowel disease. After intraduodenal administration of 5-ASA (20 mg) in rats, 91% of the drug was absorbed in the proximal small intestine. Peak serum 5-ASA concentration (55 micrograms/ml) was reached in 1 h. Approximately 61 and 6% of the administered dose were excreted in the urine and bile, respectively, in 24 h, almost exclusively in the acetylated form. When sulfapyridine (20 mg) was administered in addition to 5-ASA, 70% of the sulfapyridine was absorbed in the small intestine, peak serum concentration (50 micrograms/ml) was reached in 1 h, and 30% of the administered dose was excreted in the urine in 24 h. The results indicate that after oral administration of 5-ASA, a therapeutically significant concentration of the drug is not expected in the terminal ileum which is a common site of involvement in Crohn's disease. The therapeutic implications of these findings are discussed herein.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6123257

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  8 in total

1.  Bacterial acetylation of 5-aminosalicylic acid in faecal suspensions cultured under aerobic and anaerobic conditions.

Authors:  R A van Hogezand; H M Kennis; A van Schaik; J P Koopman; P A van Hees; J H van Tongeren
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Proctocolitis unresponsive to conventional therapy. Response to 5-aminosalicylic acid enemas.

Authors:  M S McPhee; J T Swan; W L Biddle; N J Greenberger
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

Review 3.  Clinical pharmacokinetics of slow release mesalazine.

Authors:  M De Vos
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

4.  Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man.

Authors:  C Fischer; K Maier; E Stumpf; U von Gaisberg; U Klotz
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 5.  Comparative tolerability of therapies for ulcerative colitis.

Authors:  Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

6.  Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease.

Authors:  Teuta Gjuladin-Hellon; Morris Gordon; Zipporah Iheozor-Ejiofor; Anthony K Akobeng
Journal:  Cochrane Database Syst Rev       Date:  2019-06-20

7.  Dissolution of Commercially Available Mesalamine Formulations at Various pH Levels.

Authors:  Srini Tenjarla
Journal:  Drugs R D       Date:  2015-06

8.  Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels.

Authors:  Adeyinka Abinusawa; Srini Tenjarla
Journal:  Adv Ther       Date:  2015-05-08       Impact factor: 3.845

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.